


CLAIM AMENDMENTS

Listing of Claims:

Claims 1-33 (canceled)


Claim 34 (currently amended): A macrocyclic compound of the formula (1):



and its pharmaceutically acceptable salts,
wherein

Fragment A₁ is:

~~(1-i)~~





wherein

Y is H, ~~selected from the group consisting of~~

X₁ is -CH-, and

R₁ is






and


~~X₁ is CH, (CH₂)₂ or (CH₂)₃;~~

~~when X₁ is (CH₂)₂ or (CH₂)₃, R₁ is absent;~~

~~when X₁ is CH, R₁ is a radical independently selected from the group~~

~~consisting of~~






Fragment A₂ is:

~~(2-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline, D-4-tert-butoxyproline, L-4-tert-butoxyproline; or~~

~~(2-ii)~~



wherein


X₂ is -CH-, and

R₂ is H;

~~X₂ is -CH-, (CH₂)₂ or (CH₂)₃;~~

~~when X₂ is (CH₂)₂ or (CH₂)₃, R₂ is absent;~~


~~when X₂ is -CH-, R₂ is a radical independently selected from the group consisting of~~



Fragment A₃ is:

(3-i) ~~D~~ proline, ~~L~~ proline, ~~D~~ 4-hydroxyproline, ~~L~~ 4-hydroxyproline, ~~D~~ 4-tert-butoxyproline, ~~L~~ 4-tert-butoxyproline; or


(3-ii)



wherein

X₃ is -CH-, and


R₃ is




~~X₃ is -CH-, (CH₂)₂ or (CH₂)₃;~~

~~when X₃ is (CH₂)₂ or (CH₂)₃, R₃ is absent;~~

~~when X₃ is -CH-, R₃ is a radical independently selected from the group consisting of~~







~~W₁ to W₁₆ are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;~~

W₁, W₂, W₃, and W₅ are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;


Fragment T is a radical selected from the group consisting of:





~~Fragment A1 is:~~


~~Y is selected from the group consisting of~~




X1 is ~~CH~~, ~~(CH2)2~~ or ~~(CH2)3~~;

when X1 is ~~(CH2)2~~ or ~~(CH2)3~~, R1 is absent;

when X1 is ~~CH~~, R1 is a radical independently selected from the group consisting of






Fragment A₂ is:

~~(2-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline, D-4-tert-butoxyproline, L-4-tert-butoxyproline; or~~

~~(2-ii)~~




wherein


~~X₂ is CH, (CH₂)₂ or (CH₂)₃;~~

~~when X₂ is (CH₂)₂ or (CH₂)₃, R₂ is absent;~~

~~when X₂ is CH, R₂ is a radical independently selected from the group~~

~~consisting of~~






Fragment A₃ is:—

(3-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline, D-4-tert-butoxyproline, L-4-tert-butoxyproline; or

(3-ii)




wherein


X₃ is ~~CH~~, ~~(CH₂)₂~~ or ~~(CH₂)₃~~;

when X₂ is ~~(CH₂)₂~~ or ~~(CH₂)₃~~, R₃ is absent;


when X₃ is ~~CH~~, R₃ is a radical independently selected from the group consisting of




~~W₁ to W₁₆ are each selected from the group consisting of hydrogen, and a compatible protecting group chosen from:~~




Fragment T is a radical selected from the group consisting of:





wherein (N) indicates the site of a covalent bond to the nitrogen atom of A1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A3 of formula (1).


Claim 36 (currently amended): A macrocyclic compound of the formula (1) as defined in claim 34, wherein W₁, W₂, W₃, and W₅ each represents hydrogen.÷



and its pharmaceutically acceptable salts,

wherein

Fragment A₁ is:





wherein

~~X₁ is CH, (CH₂)₂ or (CH₂)₃;~~

~~when X₁ is (CH₂)₂ or (CH₂)₃, R₁ is absent;~~

~~when X₁ is CH, R₁ is a radical independently selected from the group consisting of:~~






Fragment A₂ is:

(2-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline; or

(2-ii)




wherein


X₂ is CH, (CH₂)₂ or (CH₂)₃;

when X₂ is (CH₂)₂ or (CH₂)₃, R₂ is absent;

when X₂ is CH, R₂ is a radical independently selected from the group


consisting of





Fragment A₃ is: —

(3-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline; or
(3-ii)




wherein

X₃ is CH, (CH₂)₂ or (CH₂)₃;


when X₃ is (CH₂)₂ or (CH₂)₃, R₃ is absent;

when X₃ is CH, R₃ is a radical independently selected from the group
consisting of



wherein


Y is selected from the group consisting of




X_1 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_1 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_1 is absent;

when X_1 is $-\text{CH}-$, R_1 is a radical independently selected from the group consisting of






Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)




wherein

X₃ is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;


when X₃ is -CH-, R₃ is a radical independently selected from the group

consisting of




W₁ to W₁₆ are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 38 (new): The library according to claim 37, wherein in each compound W_1 , W_2 , W_3 , and W_5 are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:



Claim 39 (new): The library according to claim 38, wherein in each compound W_1 , W_2 , W_3 , and W_5 each represents hydrogen.

Claim 40 (new): A method of screening for a compound having antibacterial, antifungal, antiviral, or antineoplastic activity, which comprises:

- providing the library of compounds according to claim 37; and
- assaying the library of compounds against an etiological agent to identify compounds having antibacterial, antifungal, antiviral, or antineoplastic activity.

Claim 41 (new): The method of claim 40, wherein the etiological agent is selected from bacterial, fungal, viral, and neoplastic disease agents.

Claim 42 (new): An assay kit for the identification of compounds having antibacterial, antifungal, antiviral, or antineoplastic activity, the assay kit comprising a library according to claim 37, disposed in a plurality of vessels, wherein each vessel contains a compound of the library.